A prognostic signature derived from ac4C-associated genes stratifies survival and tumor immune microenvironment in cutaneous melanoma.

ABSTRACT: The clinical management of cutaneous melanoma (SKCM) is particularly challenging due to the disease's high degree of heterogeneity, which leads to unpredictable patient outcomes and highly variable responses to therapy. Clinicians are in urgent need of a reliable molecular profile system to predict patient trajectory and guide therapeutic decisions. Recent research emphasizes the pivotal role of N4-acetylcytidine (ac4C) modification, a novel epigenetic mechanism, in promoting diverse human diseases pathogenesis and progression. Nevertheless, its specific impact and the clinical relevance of ac4C-associated genes in SKCM remain to be elucidated. This study aimed to develop an "ac4C-associated Gene Signature" (AGS) to stratify patient prognosis, inform therapeutic decisions, and advance biol

SUBMITTER: Jin Q 

PROVIDER: S-EPMC12819736 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature